Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens.


Journal

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982

Informations de publication

Date de publication:
01 Oct 2019
Historique:
received: 09 04 2019
revised: 16 06 2019
accepted: 18 07 2019
pubmed: 25 7 2019
medline: 6 2 2020
entrez: 25 7 2019
Statut: ppublish

Résumé

Routine erythropoietin (Epo) therapy for neonatal anemia is presently controversial due to its modest response. We speculate that an important contributor to this modest response is that previous clinical study designs were not driven by rigorous mechanistic and kinetic insights into the complex pharmacokinetics (PK) and pharmacodynamics (PD) of Epo in this population. To address this therapeutic opportunity, we conducted a prospective clinical study to investigate the PK of Epo in very-low-birth-weight (VLBW) premature neonates using a unique Epo dosing algorithm that accounts for complex neonatal erythropoietic physiology. Twenty-seven subjects received up to 10 intravenous or subcutaneous exogenous doses of Epo (600 or 1200 U/kg) during the first 4 weeks of life. Subjects were administered two doses of Epo 1200 U/kg on days 2 and 16, and eight doses of Epo 600 U/kg on days 4, 5, 6, 7, 9, 14, 15, and 28 following birth. We have developed for the first time a mechanistic, target-mediated disposition model that provides novel insights into the mechanisms driving Epo PK in VLBW neonates. Epo association rate, k

Identifiants

pubmed: 31340188
pii: S0928-0987(19)30276-3
doi: 10.1016/j.ejps.2019.105013
pmc: PMC6733583
mid: NIHMS1537230
pii:
doi:

Substances chimiques

Erythropoietin 11096-26-7

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105013

Subventions

Organisme : NHLBI NIH HHS
ID : P01 HL046925
Pays : United States
Organisme : NCATS NIH HHS
ID : U54 TR001356
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002537
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Biopharm Drug Dispos. 1999 May;20(4):217-23
pubmed: 10440797
Exp Hematol. 2001 Apr;29(4):425-31
pubmed: 11301182
J Pharmacol Exp Ther. 2001 Aug;298(2):820-4
pubmed: 11454947
Pediatrics. 2001 Oct;108(4):934-42
pubmed: 11581447
J Pharmacol Exp Ther. 2002 Jan;300(1):346-53
pubmed: 11752135
J Pharmacokinet Pharmacodyn. 2001 Dec;28(6):507-32
pubmed: 11999290
Am J Kidney Dis. 2002 Jul;40(1):119-25
pubmed: 12087569
Biol Neonate. 2003;83(3):224-8
pubmed: 12660442
Ann N Y Acad Sci. 1959 Jun 25;77:710-24
pubmed: 13834786
AAPS PharmSci. 2004 Mar 09;6(1):E9
pubmed: 15198510
Physiol Rev. 1992 Apr;72(2):449-89
pubmed: 1557429
Pharm Res. 2005 Oct;22(10):1589-96
pubmed: 16180117
Pediatr Blood Cancer. 2006 Oct 15;47(5):572-9
pubmed: 16317760
Biochem Pharmacol. 2006 Jun 28;72(1):1-10
pubmed: 16469301
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004863
pubmed: 16856062
Clin Pharmacokinet. 2007;46(2):159-73
pubmed: 17253886
Clin Pharmacol Ther. 2007 Jun;81(6):873-9
pubmed: 17429351
Pediatr Res. 2007 Apr;61(4):451-5
pubmed: 17515870
Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):637-45
pubmed: 18071675
Pediatrics. 2008 Aug;122(2):383-91
pubmed: 18676557
J Pharmacol Exp Ther. 2010 May;333(2):528-32
pubmed: 20103588
J Pharmacol Exp Ther. 2010 Jul;334(1):327-32
pubmed: 20406858
Neoreviews. 2008 Nov 1;9(11):e520
pubmed: 20463861
Pediatr Res. 2012 Apr;71(4 Pt 1):332-7
pubmed: 22391632
Semin Perinatol. 2012 Aug;36(4):232-43
pubmed: 22818543
Pediatrics. 2012 Oct;130(4):683-91
pubmed: 23008465
Pediatr Res. 2017 Jun;81(6):865-872
pubmed: 28099423
AAPS J. 2018 Nov 26;21(1):6
pubmed: 30478521
Pediatrics. 1995 Jan;95(1):9-10
pubmed: 7770317
Clin Pharmacol Ther. 1994 Sep;56(3):248-52
pubmed: 7924119
J Appl Physiol (1985). 1996 Jan;80(1):140-8
pubmed: 8847295

Auteurs

Ronilda D'Cunha (R)

Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.

Robert Schmidt (R)

Department of Pediatrics Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.

John A Widness (JA)

Department of Pediatrics Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.

Donald M Mock (DM)

Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, USA.

Xiaoyu Yan (X)

School of Pharmacy, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong.

Gretchen A Cress (GA)

Department of Pediatrics Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.

Denison Kuruvilla (D)

Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA; MedImmune, LLC., San Francisco, CA, USA.

Peter Veng-Pedersen (P)

Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.

Guohua An (G)

Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA. Electronic address: guohua-an@uiowa.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH